person · Reporting owner
Kelsey Stephen Michael
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jiya Acquisition Corp.JYAC · Entity 123583 | Director | November 18, 2020 | November 19, 2020 |
| Revolution Medicines, Inc.RVMD · Entity 606 | See Remarks | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jiya Acquisition Corp.
Report date November 18, 2020 · Filed November 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.
F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 291,791 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 85 · Balance 291,791 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 286,307 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 5,484 · Balance 286,307 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 65,613 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 65,613 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 9,384 | $4.73 | $44,386.32 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 00:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-017064 · doc1.xml · derivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,955 Underlying: Common Stock · 100 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 00:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 100 | $34.02 | $3,402.00 |
DisclosureSEC source: 0001567619-20-017064 · doc1.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,329 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 00:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 100 | $4.73 | $473.00 |
DisclosureSEC source: 0001567619-20-017064 · doc1.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 00:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 98 | $33.00 | $3,234.00 |
DisclosureSEC source: 0001567619-20-017064 · doc1.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,329 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 21, 2020 Filed Sep 24, 2020 00:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 14,902 | $33.00 | $491,804.75 |
DisclosureSEC source: 0001567619-20-017064 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,427 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $33.00 to $33.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 18, 2020 Filed Sep 19, 2020 00:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 637 | $31.03 | $19,767.38 |
DisclosureSEC source: 0001567619-20-016894 · doc1.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,329 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $31.00 to $31.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 17, 2020 Filed Sep 19, 2020 00:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 11,363 | $31.03 | $352,556.39 |
DisclosureSEC source: 0001567619-20-016894 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,966 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $31.00 to $31.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,002 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · derivative · entry 9 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,055 Underlying: Common Stock · 1,002 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,540 | $29.00 | $44,660.00 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · nonDerivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,329 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,002 | $29.16 | $29,220.22 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · nonDerivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,869 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 1,002 | $4.73 | $4,739.46 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 100 | $29.04 | $2,904.00 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,869 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · derivative · entry 8 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,057 Underlying: Common Stock · 600 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 800 | $29.09 | $23,274.00 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,969 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 600 | $29.02 | $17,409.00 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,769 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 01:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 600 | $4.73 | $2,838.00 |
DisclosureSEC source: 0001567619-20-016619 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 03, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · derivative · entry 15 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,657 Underlying: Common Stock · 700 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 03, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 700 | $29.06 | $20,342.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 11 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,769 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The transaction was executed in multiple trades in prices ranging from $29.03 to $29.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 03, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 700 | $29.08 | $20,356.98 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 10 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,469 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $29.03 to $29.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 03, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 700 | $4.73 | $3,311.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 9 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · derivative · entry 14 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,357 Underlying: Common Stock · 100 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 726 | $29.02 | $21,065.47 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 8 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,469 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 100 | $29.08 | $2,908.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,195 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 100 | $4.73 | $473.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,283 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · derivative · entry 13 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,457 Underlying: Common Stock · 9,283 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 717 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · derivative · entry 12 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,666 Underlying: Common Stock · 717 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,071 | $28.24 | $143,219.75 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,195 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $28.04 to $28.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,908 | $27.54 | $80,096.79 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,266 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $27.01 to $27.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,021 | $26.43 | $53,405.73 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,174 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $26.00 to $26.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 9,283 | $4.73 | $43,908.59 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 717 | $4.09 | $2,932.53 |
DisclosureSEC source: 0001567619-20-016457 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 23:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 118 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001567619-20-016180 · doc1.xml · derivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,383 Underlying: Common Stock · 118 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 23:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 118 | $29.00 | $3,422.00 |
DisclosureSEC source: 0001567619-20-016180 · doc1.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,195 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 23:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 118 | $4.09 | $482.62 |
DisclosureSEC source: 0001567619-20-016180 · doc1.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001567619-20-016180 · doc1.xml · derivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,501 Underlying: Common Stock · 800 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 814 | $29.01 | $23,617.40 |
DisclosureSEC source: 0001567619-20-016180 · doc1.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,195 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 800 | $29.01 | $23,208.00 |
DisclosureSEC source: 0001567619-20-016180 · doc1.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,009 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 800 | $4.09 | $3,272.00 |
DisclosureSEC source: 0001567619-20-016180 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · derivative · entry 12 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,301 Underlying: Common Stock · 4,900 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,100 | $28.06 | $30,861.05 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 10 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,009 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $28.00 to $28.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 1,100 | $4.09 | $4,499.00 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 9 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,800 | $27.40 | $104,134.06 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 8 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,009 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $27.00 to $27.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 3,800 | $4.09 | $15,542.00 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,100 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · derivative · entry 11 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,201 Underlying: Common Stock · 10,100 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 300 | $27.55 | $8,265.00 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,009 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $27.51 to $27.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 300 | $4.09 | $1,227.00 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 702 | $26.77 | $18,792.26 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,009 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $26.41 to $27.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 702 | $4.09 | $2,871.18 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 9,098 | $25.79 | $234,636.51 |
DisclosureSEC source: 0001567619-20-015579 · doc1.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,009 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.35 to $26.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.